Aktienanalyse zu Bruker Corporation (BRKR)BRKRBruker Corporation

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Bruker Corp is currently trading at $54.80, which is below several analyst price targets, including $70 from Barclays and $72 from Guggenheim, indicating potential upside. However, the stock has a low RSI of 26.87, suggesting it is oversold, and a negative 5-day change of -6.87% indicates recent weakness. The main risk is the significant net income loss of $62.9 million reported in Q2 2026, which raises concerns about profitability.

14 analysts cover BRKR: 2 rate it Buy, 10 Hold and 2 Sell. The average price target is 52.18.